8-KLeadership ChangesRegulation FDExhibits & Filings

MCKESSON CORP 8-K Report, Executive Changes (Dec 18, 2017)

Filed December 18, 2017For Securities:MCK

Summary

McKesson Corporation (MCK) announced a key executive transition in an 8-K filing on December 18, 2017. Britt Vitalone has been appointed Executive Vice President and Chief Financial Officer, effective January 1, 2018. This appointment follows the departure of James A. Beer, who will be leaving McKesson to assume the CFO role at Atlassian Corporation PLC. The company is signaling continuity in financial leadership with an internal promotion. Mr. Vitalone brings extensive experience within McKesson, having most recently served as Senior Vice President and Chief Financial Officer of U.S. Pharmaceutical and McKesson Specialty Health. His prior roles include significant financial planning, M&A, and business unit CFO responsibilities within the company, along with experience at other prominent corporations. Investors will be looking for Vitalone's continued guidance in navigating the company's financial strategy and operational execution.

Key Highlights

  • 1Britt Vitalone appointed as Executive Vice President and Chief Financial Officer, effective January 1, 2018.
  • 2James A. Beer resigns as CFO, effective December 31, 2017, to join Atlassian Corporation PLC.
  • 3Mr. Vitalone is an internal promotion with a proven track record at McKesson.
  • 4Vitalone's experience includes leadership in U.S. Pharmaceutical and Specialty Health financial operations.
  • 5Prior roles at McKesson involved corporate financial planning, M&A, and business unit finance.
  • 6The filing includes a press release as an exhibit, detailing the CFO transition.

Frequently Asked Questions

Britt Vitalone has been appointed as the new Executive Vice President and Chief Financial Officer of McKesson Corporation, effective January 1, 2018.

James A. Beer is leaving McKesson to become the chief financial officer of Atlassian Corporation PLC.

Britt Vitalone has extensive experience within McKesson, most recently as Senior Vice President and Chief Financial Officer of U.S. Pharmaceutical and McKesson Specialty Health. He has also held positions in corporate financial planning, mergers & acquisitions, and business unit finance at McKesson, as well as prior financial leadership roles at General Electric Financial Assurance, CarMax, and Bausch & Lomb.

No, the compensation for Mr. Vitalone associated with his new position had not been determined at the time of the filing.